Gene · 92521
Papers3,158
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,741 to 1,760 of 3,158
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A SARS-CoV-2 -human metalloproteome interaction map. | J Inorg Biochem | 2021 | 33813307 | PubTator, text mining | PubMed |
| X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease. | Science | 2021 | 33811162 | PubTator, text mining | PubMed |
| An Overview of Current Knowledge of Deadly CoVs and Their Interface with Innate Immunity. | Viruses | 2021 | 33810391 | PubTator, text mining | PubMed |
Escherichia coli Heat-Labile Enterotoxin B Subunit Combined with Ginsenoside Rg1 as an Intranasal Adjuvant Triggers Type I Interferon Signaling Pathway and Enhances Adaptive Immune Responses to an Inactivated PRRSV Vaccine in ICR Mice. | Vaccines (Basel) | 2021 | 33809809 | PubTator, text mining | PubMed |
| Characterisation of a G2P[4] Rotavirus Outbreak in Western Australia, Predominantly Impacting Aboriginal Children. | Pathogens | 2021 | 33809709 | PubTator, text mining | PubMed |
| Repurposing of Some Natural Product Isolates as SARS-COV-2 Main Protease Inhibitors via In Vitro Cell Free and Cell-Based Antiviral Assessments and Molecular Modeling Approaches. | Pharmaceuticals (Basel) | 2021 | 33806331 | PubTator, text mining | PubMed |
| Expanding Our Understanding of COVID-19 from Biomedical Literature Using Word Embedding. | Int J Environ Res Public Health | 2021 | 33804131 | PubTator, text mining | PubMed |
| SARS-CoV-2 Entry Related Viral and Host Genetic Variations: Implications on COVID-19 Severity, Immune Escape, and Infectivity. | Int J Mol Sci | 2021 | 33802729 | PubTator, text mining | PubMed |
| Role of Mitochondria in Viral Infections. | Life (Basel) | 2021 | 33799853 | PubTator, text mining | PubMed |
| Molecular epidemiology analysis of early variants of SARS-CoV-2 reveals the potential impact of mutations P504L and Y541C (NSP13) in the clinical COVID-19 outcomes. | Infect Genet Evol | 2021 | 33798758 | PubTator, text mining | PubMed |
| Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors. | Nat Commun | 2021 | 33795671 | PubTator, text mining | PubMed |
| Viral Respiratory Pathogens and Lung Injury. | Clin Microbiol Rev | 2021 | 33789928 | PubTator, text mining | PubMed |
| The potential of miRNA-based therapeutics in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A review. | J Pharm Anal | 2021 | 33782640 | PubTator, text mining | PubMed |
| Precision therapeutic targets for COVID-19. | Virol J | 2021 | 33781287 | PubTator, text mining | PubMed |
| Conflicting and ambiguous names of overlapping ORFs in the SARS-CoV-2 genome: A homology-based resolution. | Virology | 2021 | 33774510 | PubTator, text mining | PubMed |
| Clinical, Serological, Whole Genome Sequence Analyses to Confirm SARS-CoV-2 Reinfection in Patients From Mumbai, India. | Front Med (Lausanne) | 2021 | 33768104 | PubTator, text mining | PubMed |
| Structural and Drug Screening Analysis of the Non-structural Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 Virus Extracted From Indian Coronavirus Disease 2019 Patients. | Front Genet | 2021 | 33767730 | PubTator, text mining | PubMed |
| Plant Products as Inhibitors of Coronavirus 3CL Protease. | Front Pharmacol | 2021 | 33767619 | PubTator, text mining | PubMed |
| Characterization of SARS-CoV-2 proteins reveals Orf6 pathogenicity, subcellular localization, host interactions and attenuation by Selinexor. | Cell Biosci | 2021 | 33766124 | PubTator, text mining | PubMed |
| Direct Observation of Protonation State Modulation in SARS-CoV-2 Main Protease upon Inhibitor Binding with Neutron Crystallography. | J Med Chem | 2021 | 33755450 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/92521/papers?page=88